ClinicalTrials.Veeva

Menu

Semaphorins 3A and 4D Levels in Heart Failure Patients

B

Bnai Zion Medical Center

Status

Unknown

Conditions

Heart Failure

Treatments

Other: Biospecimen retention

Study type

Observational

Funder types

Other

Identifiers

NCT02406716
NW-2401-ZV

Details and patient eligibility

About

This study hypothesis is that Semaphorins 3A and 4D levels are overexpressed in patients with heart failure. Study protocol:

Hospitallized patients with new onset or previously diagnosed heart failure will be recruited to the study. Control group will include healthy people with no medical records or chronic treatment at the same age range. After signing an informed constent form, full medical history and blood samples will be collected. A second blood sample will be collected 8 weeks later, assuming the patient was discharged and not hospitalized since than. The blood samples will be analyzed by Bnai Zion Medical Center Immunology labs for the above semaphorins levels in the heart failure group and control group. Statistical analysis will then commence for possible correlatoion with different clinical parameters.

Full description

In few previous published studies, Semaphorins 3A levels are overexpressed in patients with heart failure. The aim of our study is the compare semaphorin 3A and 4D in patients with acute decompansated heart failure with healthy donors. Second aim is to compare semaphorin level in the same patients in time of hospitalization and few weeks later when the heart failure presumingly controled. Statistical analysis will then commense for possible correlatoion with different clinical parameters like NYHA (new york heart association) status of the patient, lenghts of hospitalization and BNP (brain natriuretic peptide) levels at time of admition.

Enrollment

120 estimated patients

Sex

All

Ages

50 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients with new onset or previously diagnosed heart failure.
  • Heart failure diagnosis can be based on clinical judgment, echocardiography or elevated BNP levels

Exclusion criteria

  • Patients with acute myocardial infarction diagnosed clinicly and labratory

Trial design

120 participants in 2 patient groups

HF
Description:
Heart failure patients
Treatment:
Other: Biospecimen retention
Controls
Description:
Healthy donors
Treatment:
Other: Biospecimen retention

Trial contacts and locations

0

Loading...

Central trial contact

Nadav Willner, MD.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems